Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

HDAC inhibition synergizes with ALK inhibitors to overcome resistance in a novel ALK mutated lung adenocarcinoma model.

Lung cancer (Amsterdam, Netherlands) - 1 Jun 2020

Stockhammer Paul, Ho Cassandra Su Lyn, Hegedus Luca, Lotz Gabor, Molnár Eszter, Bankfalvi Agnes, Herold Thomas, Kalbourtzis Stavros, Ploenes Till, Eberhardt Wilfried E E, Schuler Martin, Aigner Clemens, Schramm Alexander, Hegedus Balazs

Abstract excerpt

OBJECTIVES: Somatic chromosomal rearrangements resulting in ALK fusion oncogenes are observed in 3-7 % of lung adenocarcinomas. ALK tyrosine kinase inhibitors (ALKi) induce initially response, however, various resistance mechanisms limit their efficacy. Novel therapeutic approaches are of utmost importance to tailor these targeted therapies. MATERIALS AND METHODS: A synchronous ALK-rearranged and mutated lung...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma of Lung
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Lung Neoplasms

Share to Mutation

Share to Protein Kinase Inhibitors

Source

Identifiers

PMID: 32353632
DOI: 10.1016/j.lungcan.2020.04.002

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

HDAC inhibition synergizes with ALK inhibitors to overcome resistance in a novel ALK mutated lung adenocarcinoma model.PMID 32353632Read ↗

BRAF V600E mutation and MET amplification as resistance pathways of the second-generation anaplastic lymphoma kinase (ALK) inhibitor alectinib in lung cancer.Semantic proximity Read ↗

ALK is a critical regulator of the MYC-signaling axis in ALK positive lung cancerSemantic proximity Read ↗

PI3Kβ inhibition restores ALK inhibitor sensitivity in ALK-rearranged lung cancerSemantic proximity Read ↗

A Pan-Cancer Review of ALK Mutations: Implications for Carcinogenesis and Therapy.Semantic proximity Read ↗

Activation of the Met kinase confers acquired drug resistance in FGFR-targeted lung cancer therapySemantic proximity Read ↗

Targeting ALK: Precision Medicine Takes on Drug Resistance.Semantic proximity Read ↗

Targeting Anaplastic Lymphoma Kinase in Lung CancerSemantic proximity Read ↗

Epithelial-to-Mesenchymal Transition Is a Mechanism of ALK Inhibitor Resistance in Lung Cancer Independent of ALK Mutation StatusSemantic proximity Read ↗

KANK1 regulates paclitaxel resistance in lung adenocarcinoma A549 cellsSemantic proximity Read ↗

Clinical challenges in targeting anaplastic lymphoma kinase in advanced non-small cell lung cancer.Semantic proximity Read ↗

Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine.Semantic proximity Read ↗

BRAF V600E mutation as a novel mechanism of acquired resistance to ALK inhibition in ALK-rearranged lung adenocarcinoma: A case report.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.